Evaluating the role of intravenous pentoxifylline on successfullness of stenting in patients with myocardial infarction

Evaluating the role of intravenous Pentoxifylline administration on increasing primary percutaneous coronary intervention (PPCI) success in ST elevation myocardial infarction (STEMI) patient

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120111008698N24

Enrollment

320

Registered

2019-08-02

Start date

2019-06-20

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Administration of intravenous pentoxifylline

50 mg IV bolus, then 50 mg IV infusion in 30 minutes. Intervention 2: Control group: Administration of solvent: NaCl 0.9 % serum.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 18 who are candidate for primary PCI. Pain or chest discomfort greater than or equal to 20 minutes, less than or equal to 12 hours, and ST elevation = 1 mm in the adjacent limb leads and precordial leads except for V2, V3, or ST elevation = 2 mm in V2, V3 in men or ST height = 1.5 mm in V2, V3 in women. Obtain informed consent from all patients before enrollment.

Exclusion criteria

Exclusion criteria: Start angina more than 12 hours CPR before transition to cath-lab Patients with history of cardiac transplantation Patients with history of PCI or CABG in last month Patients who received thrombolytic Current use of pentoxyfilline Use of ketorolac in last 24 hours

Design outcomes

Primary

Measure	Time frame
Coronary blood flow and myocardial perfusion. Timepoint: during angiography. Method of measurement: TIMI flow criteria and observations during the angiography.	—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: baseline and 48 hours after PCI. Method of measurement: blood sample.;TNT. Timepoint: baseline and 24 hours and 48 hours after PCI. Method of measurement: blood sample.;30 day MACE. Timepoint: one month after PCI. Method of measurement: follow-up visit or phone call.;TFC. Timepoint: during angiography. Method of measurement: TIMI frame count and observations during the angiography.;MBG. Timepoint: during angiography. Method of measurement: myocardial blush grade and observations during the angiography.	—

Measure

Time frame

Hs-CRP. Timepoint: baseline and 48 hours after PCI. Method of measurement: blood sample.;TNT. Timepoint: baseline and 24 hours and 48 hours after PCI. Method of measurement: blood sample.;30 day MACE. Timepoint: one month after PCI. Method of measurement: follow-up visit or phone call.;TFC. Timepoint: during angiography. Method of measurement: TIMI frame count and observations during the angiography.;MBG. Timepoint: during angiography. Method of measurement: myocardial blush grade and observations during the angiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hessam Kakavand

Tehran University of Medical Sciences

hessamkakavand@yahoo.com+98 21 8802 9261

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026